Trial Profile
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory Choroidal Neovascularization (CNV) in Young Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- Acronyms ALINEA
- 01 Feb 2023 Results published in the Acta Ophthalmologica
- 06 Nov 2019 Status changed from active, no longer recruiting to completed.
- 22 Oct 2018 Planned End Date changed from 1 Sep 2020 to 1 Jan 2020.